We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Multifaceted Intervention Reduces In-Patient Laboratory Costs

By LabMedica International staff writers
Posted on 16 Feb 2016
Print article
Image: A phlebotomist examining a blood sample to be used for multiple tests ordered by the physician (Photo courtesy of University of Utah Medical Center).
Image: A phlebotomist examining a blood sample to be used for multiple tests ordered by the physician (Photo courtesy of University of Utah Medical Center).
Image: Photomicrograph of a blood smear, part of the complete blood count (Photo courtesy of the University of Utah Medical Center).
Image: Photomicrograph of a blood smear, part of the complete blood count (Photo courtesy of the University of Utah Medical Center).
A tool called Value Driven Outcomes has been developed to reduce superfluous laboratory testing and when integrated into a quality improvement initiative laboratory costs decreased by nearly 10% per visit.

Unnecessary laboratory testing contributes to the estimated USD 910 billion wasted each year in health care in the USA. Beyond costs, laboratory testing is an important patient safety issue. The sheer number of tests ordered can lead to incidental findings that result in unnecessary follow-up testing and potentially harmful interventions, and early morning blood draws can prevent much needed rest. Vulnerable patients can even develop anemia and associated complications from over-testing.

Scientists at the University of Utah Medical Center (Salt Lake City, UT) carried out a retrospective, controlled, interrupted time series (ITS) study to evaluate the impact of a multifaceted laboratory reduction intervention on laboratory costs. Measurements were made of the primary outcomes of laboratory cost per day and per visit. Another measurement was the outcomes of number of basic metabolic panel (BMP), comprehensive metabolic panel (CMP), complete blood count (CBC), and prothrombin time/international normalized ratio tests per day; length of stay (LOS); and 30-day readmissions.

The results of the interventions over a 15-month period were tangible. An intervention group of 6,310 hospitalist patient visits were compared to a control group of 25,586 non-hospitalist visits. The interventions reduced the mean cost per day for laboratory testing from USD 138 to USD 123 and the mean cost per visit decreased from USD 618 to USD 558. There was also a significant reduction in laboratory cost per day, laboratory cost per visit, and the number of tests per day.

The authors concluded that a multifaceted approach, including education, rounding checklist implementation, cost feedback, and financial incentives, to laboratory reduction demonstrated a significant reduction in laboratory cost per day and per visit, as well as common tests per day at a major academic medical center.

Peter Yarbrough, MD, an assistant professor of internal medicine and lead author of the study, said, “Frequently, patients do need labs every morning, but that can create a culture where you're ordering tests without really thinking about what you're going to do with the results. Prior to VDO, we never had cost information. Most of the tests don't cost very much, but their numbers were so high that the total cost became significant.” The study was published on February 4, 2016, in the Journal of Hospital Medicine.

Related Links:

University of Utah Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.